Gambaran Umum
Genprex, Inc., headquartered in the United States, operates within the biotechnology sector, focusing primarily on developing gene therapy-based treatments for cancer and diabetes. The company's flagship product, REQORSA® (quaratusugene ozeplasmid), is designed to administer tumor suppressor genes by encapsulating them into nanoparticles which are then introduced to deficient cells, aiming to combat non-small cell lung cancer. This innovative approach is part of Genprex's broader strategy to integrate its proprietary technology, Oncoprex™ nanoparticle delivery system, to potentially enhance the clinical efficacy of existing cancer drugs. Additionally, Genprex is exploring gene therapies in the treatment of diabetes, signifying its expansion into other serious health conditions beyond oncology.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Genprex, Inc. per 2025 Jun 30 adalah -17.31 MM.
- Nilai net income untuk Genprex, Inc. per 2025 Jun 30 adalah -17.56 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -17.31 | -17.56 | |
2025-03-31 | -19.15 | -19.38 | |
2024-12-31 | -21.17 | -21.39 | |
2024-09-30 | -22.81 | -22.71 | |
2024-06-30 | -26.27 | -26.14 | |
2024-03-31 | -27.79 | -27.63 | |
2023-12-31 | -31.06 | -30.86 | |
2023-09-30 | -31.67 | -31.45 | |
2023-06-30 | -30.05 | -29.85 | |
2023-03-31 | -27.78 | -27.63 | |
2022-12-31 | -23.83 | -23.74 | |
2022-09-30 | -24.00 | -23.97 | |
2022-06-30 | -21.27 | -21.26 | |
2022-03-31 | -19.49 | -19.49 | |
2021-12-31 | -20.67 | -20.66 | |
2021-09-30 | -19.15 | -19.14 | |
2021-06-30 | -18.49 | -18.48 | |
2021-03-31 | -18.88 | -18.87 | |
2020-12-31 | -17.96 | -17.94 | |
2020-09-30 | -15.16 | -15.14 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Genprex, Inc. pada 2025 Jun 30 adalah -1.27.
- laba per saham yang terdilusi untuk Genprex, Inc. pada 2025 Jun 30 adalah -1.27.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -1.27 | -1.27 |
2025-03-31 | -2.58 | -2.58 |
2024-12-31 | -5.34 | |
2024-09-30 | -10.36 | -10.36 |
2024-06-30 | -15.57 | -15.57 |
2024-03-31 | -19.07 | -19.07 |
2023-12-31 | -22.56 | |
2023-09-30 | -24.27 | -24.27 |
2023-06-30 | -24.18 | -24.18 |
2023-03-31 | -22.86 | -22.86 |
2022-12-31 | -19.80 | |
2022-09-30 | -20.02 | -20.02 |
2022-06-30 | -17.79 | -17.79 |
2022-03-31 | -16.35 | -16.35 |
2021-12-31 | -17.55 | |
2021-09-30 | -16.99 | -16.99 |
2021-06-30 | -17.22 | -17.22 |
2021-03-31 | -18.90 | -18.90 |
2020-12-31 | -20.20 | |
2020-09-30 | -20.23 | -20.23 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Genprex, Inc. per 2025 Jun 30 adalah -13.31 MM.
- Nilai cash from investing activities untuk Genprex, Inc. per 2025 Jun 30 adalah -0.77 MM.
- Nilai kas dari aktivitas pendanaan untuk Genprex, Inc. per 2025 Jun 30 adalah 12.97 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -13.31 | -0.77 | 12.97 |
2025-03-31 | -16.01 | 0.02 | 11.25 |
2024-12-31 | -17.15 | 0.00 | 12.01 |
2024-09-30 | -19.02 | 0.76 | 8.03 |
2024-06-30 | -21.57 | 0.74 | 13.33 |
2024-03-31 | -23.10 | -0.07 | 13.31 |
2023-12-31 | -24.74 | -0.07 | 10.59 |
2023-09-30 | -24.32 | -0.08 | 10.60 |
2023-06-30 | -24.11 | -0.08 | 4.09 |
2023-03-31 | -20.48 | -0.08 | 4.09 |
2022-12-31 | -17.62 | -0.06 | 0.01 |
2022-09-30 | -16.29 | -0.21 | 0.00 |
2022-06-30 | -14.40 | -0.03 | 0.24 |
2022-03-31 | -12.89 | 0.02 | 0.35 |
2021-12-31 | -14.28 | -0.08 | 25.68 |
2021-09-30 | -14.96 | -2.25 | 38.17 |
2021-06-30 | -14.34 | -2.27 | 38.72 |
2021-03-31 | -14.88 | -2.31 | 41.18 |
2020-12-31 | -13.94 | -2.34 | 41.59 |
2020-09-30 | -11.76 | -0.09 | 30.36 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Genprex, Inc. pada 2025 Jun 30 adalah -0.28.
- p/libro untuk Genprex, Inc. pada 2025 Jun 30 adalah 1.42.
- p/tbv untuk Genprex, Inc. pada 2025 Jun 30 adalah 1.42.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -0.28 | 1.42 | 1.42 |
2025-03-31 | -0.10 | 1.39 | 1.39 |
2024-12-31 | -0.32 | 4.34 | 4.34 |
2024-09-30 | -0.05 | 0.31 | 0.38 |
2024-06-30 | -0.15 | 0.47 | 0.51 |
2024-03-31 | -0.13 | 0.33 | 0.35 |
2023-12-31 | -0.43 | 1.10 | 1.17 |
2023-09-30 | -0.78 | 1.94 | 2.07 |
2023-06-30 | -1.54 | 2.31 | 2.40 |
2023-03-31 | -2.09 | 1.72 | |
2022-12-31 | 2.53 | 2.59 | |
2022-09-30 | 2.12 | 2.16 | |
2022-06-30 | -3.51 | 1.79 | 1.82 |
2022-03-31 | 2.37 | ||
2021-12-31 | -3.27 | 1.39 | 1.41 |
2021-09-30 | -6.92 | 2.68 | 2.72 |
2021-06-30 | |||
2021-03-31 | -4.39 | 1.64 | 1.66 |
2020-12-31 | -4.21 | 2.44 | 2.49 |
2020-09-30 | -4.56 | 3.01 | 3.08 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Genprex, Inc. pada 2025 Jun 30 adalah -9.53.
- EBIT (3 tahun) / EV untuk Genprex, Inc. pada 2025 Jun 30 adalah -12.35.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -9.53 | -12.35 |
2025-03-31 | -27.75 | -31.76 |
2024-12-31 | -3.95 | -4.49 |
2024-09-30 | 23.26 | 23.80 |
2024-06-30 | 6.69 | 5.98 |
2024-03-31 | 4.11 | 3.26 |
2023-12-31 | -17.67 | -13.71 |
2023-09-30 | -2.22 | -1.69 |
2023-06-30 | -1.13 | -0.90 |
2023-03-31 | -1.04 | -0.92 |
2022-12-31 | -0.51 | -0.43 |
2022-09-30 | -0.52 | -0.47 |
2022-06-30 | -0.60 | -0.55 |
2022-03-31 | 0.00 | -0.10 |
2021-12-31 | -0.93 | -0.77 |
2021-09-30 | -0.22 | -0.18 |
2021-06-30 | ||
2021-03-31 | -0.53 | -0.44 |
2020-12-31 | -0.37 | -0.28 |
2020-09-30 | -0.32 | -0.25 |
Efektivitas Manajemen
- roa untuk Genprex, Inc. pada 2025 Jun 30 adalah -2.93.
- roe untuk Genprex, Inc. pada 2025 Jun 30 adalah -4.46.
- roic untuk Genprex, Inc. pada 2025 Jun 30 adalah -5.01.
- croic untuk Genprex, Inc. pada 2025 Jun 30 adalah -1.23.
- ocroic untuk Genprex, Inc. pada 2025 Jun 30 adalah -4.14.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -2.93 | -4.46 | -5.01 | -1.23 | -4.14 |
2025-03-31 | -1.81 | -2.59 | -13.64 | -6.14 | -10.96 |
2024-12-31 | -2.13 | -3.06 | -13.64 | -6.14 | -10.96 |
2024-09-30 | -1.57 | -2.12 | -6.02 | -1.73 | -4.78 |
2024-06-30 | -1.18 | -1.49 | -3.15 | -1.13 | -2.64 |
2024-03-31 | -1.25 | -1.41 | -2.56 | -1.12 | -1.99 |
2023-12-31 | -1.05 | -1.14 | -2.56 | -1.12 | -1.99 |
2023-09-30 | -0.86 | -0.92 | -2.48 | -1.67 | -2.01 |
2023-06-30 | -0.80 | -0.85 | -2.48 | -1.67 | -2.01 |
2023-03-31 | -0.57 | -0.61 | -1.49 | -0.89 | -1.12 |
2022-12-31 | -0.49 | -0.50 | -0.82 | -0.60 | -0.60 |
2022-09-30 | -0.43 | -0.44 | -0.82 | -0.60 | -0.60 |
2022-06-30 | -0.39 | -0.39 | -0.62 | -0.44 | -0.45 |
2022-03-31 | 0.00 | 0.00 | -0.51 | ||
2021-12-31 | -0.61 | -0.62 | -0.47 | 0.27 | -0.33 |
2021-09-30 | -0.79 | -0.80 | -0.42 | 0.46 | -0.30 |
2021-06-30 | -0.75 | -0.75 | -0.39 | 0.46 | -0.30 |
2021-03-31 | -0.77 | -0.79 | -0.37 | 0.48 | -0.30 |
2020-12-31 | -5.08 | -5.93 | -0.58 | 0.82 | -0.45 |
2020-09-30 | -3.72 | -4.29 | -0.66 | 0.81 | -0.51 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1595248 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |